BSX Stock Overview
Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BSX from our risk checks.
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$85.50 |
| 52 Week High | US$86.50 |
| 52 Week Low | US$50.02 |
| Beta | 0.80 |
| 11 Month Change | 6.21% |
| 3 Month Change | 20.42% |
| 1 Year Change | 70.66% |
| 33 Year Change | 140.37% |
| 5 Year Change | n/a |
| Change since IPO | 354.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| BSX | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 2.4% | -4.9% | -1.5% |
| 1Y | 70.7% | -5.6% | 7.9% |
Return vs Industry: BSX exceeded the German Medical Equipment industry which returned -5.6% over the past year.
Return vs Market: BSX exceeded the German Market which returned 7.9% over the past year.
Price Volatility
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 3.4% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BSX has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BSX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 48,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Boston Scientific Corporation Fundamentals Summary
| BSX fundamental statistics | |
|---|---|
| Market cap | €125.82b |
| Earnings (TTM) | €1.69b |
| Revenue (TTM) | €15.02b |
74.3x
P/E Ratio8.4x
P/S RatioIs BSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSX income statement (TTM) | |
|---|---|
| Revenue | US$15.91b |
| Cost of Revenue | US$4.97b |
| Gross Profit | US$10.94b |
| Other Expenses | US$9.15b |
| Earnings | US$1.79b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.22 |
| Gross Margin | 68.74% |
| Net Profit Margin | 11.27% |
| Debt/Equity Ratio | 51.9% |
How did BSX perform over the long term?
See historical performance and comparison